FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Inclusion Criteria: Women with diagnosed, histologically confirmed, clinical stage I-III, HR+ invasive breast cancer as defined by ASCO CAP guidelines for whom adjuvant endocrine therapy would be indicated. BMI of 18-40 kg/m2 Age 40-65 Currently on endocrine therapy (tamoxifen or aromatase inhibitors). Willing and able to provide written informed consent/assent for the trial. Postmenopausal as defined by spontaneous amenorrhea for at least 12 consecutive months, spontaneous amenorrhea for at least 6 months with biochemical criteria or menopause (FSH \> 40 IU/L), or bilateral oophorectomy for at least 6 weeks before the screening visit, or if premenopausal chemically suppressed by GnRH agonist therapy with ultrasensitive estradiol level \<10. On endocrine therapy for a minimum of 3 months and has planned duration of 12 weeks left in the treatment regimen. Experiencing an average of seven or more moderate to severe hot flashes per day over a 7-day period as documented by Symptom Diary during the Screening Period and seeking treatment or relief for VMS. Able to swallow oral formulation of the study agent. Exclusion Criteria: Participants who have a diagnosis of stage IV metastatic disease. Receiving any other cancer treatment other than endocrine therapy. This includes chemotherapy, targeted therapies, and immunotherapy. Receiving cytochrome CYP1A2 inhibitors. Participants who have received any treatment for vasomotor symptoms (prescription, over the counter, or he…